Cargando…
First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
Thirty-one consecutive patients with advanced epithelial ovarian cancer entered a phase II study with cisplatin and etoposide combination chemotherapy. None of them had received prior chemotherapy or radiotherapy. Most patients had advanced (88%) or far advanced (61%) disease. All 31 patients are ev...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247295/ https://www.ncbi.nlm.nih.gov/pubmed/2803952 |
_version_ | 1782150951205863424 |
---|---|
author | Athanassiou, A. E. Bafaloukos, D. Pectasides, D. Dimitriadis, M. Varthalitis, I. Barbounis, V. |
author_facet | Athanassiou, A. E. Bafaloukos, D. Pectasides, D. Dimitriadis, M. Varthalitis, I. Barbounis, V. |
author_sort | Athanassiou, A. E. |
collection | PubMed |
description | Thirty-one consecutive patients with advanced epithelial ovarian cancer entered a phase II study with cisplatin and etoposide combination chemotherapy. None of them had received prior chemotherapy or radiotherapy. Most patients had advanced (88%) or far advanced (61%) disease. All 31 patients are evaluable for toxicity which was significant and led to removal of five (16%) patients from the study. Of the 23 patients evaluable for response there were four clinical complete (CR) and eight partial (PR) responders for a total clinical response rate of 52% of evaluable patients and 39% of all patients. Eight patients (four clinical CR and four good PR) have undergone second look laparotomy with pathological CR in one of the clinical CR patients. Median survival time for responders and non-responders is 19 and 8 months respectively. The results obtained appear to be inferior to other cisplatin based combinations. Although this could be attributed to the unusually high proportion of patients with bulky disease and stage IV patients, we feel that the study suggests that etoposide did not add any benefits for this patient population to cisplatin as a single agent. |
format | Text |
id | pubmed-2247295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1989 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22472952009-09-10 First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. Athanassiou, A. E. Bafaloukos, D. Pectasides, D. Dimitriadis, M. Varthalitis, I. Barbounis, V. Br J Cancer Research Article Thirty-one consecutive patients with advanced epithelial ovarian cancer entered a phase II study with cisplatin and etoposide combination chemotherapy. None of them had received prior chemotherapy or radiotherapy. Most patients had advanced (88%) or far advanced (61%) disease. All 31 patients are evaluable for toxicity which was significant and led to removal of five (16%) patients from the study. Of the 23 patients evaluable for response there were four clinical complete (CR) and eight partial (PR) responders for a total clinical response rate of 52% of evaluable patients and 39% of all patients. Eight patients (four clinical CR and four good PR) have undergone second look laparotomy with pathological CR in one of the clinical CR patients. Median survival time for responders and non-responders is 19 and 8 months respectively. The results obtained appear to be inferior to other cisplatin based combinations. Although this could be attributed to the unusually high proportion of patients with bulky disease and stage IV patients, we feel that the study suggests that etoposide did not add any benefits for this patient population to cisplatin as a single agent. Nature Publishing Group 1989-11 /pmc/articles/PMC2247295/ /pubmed/2803952 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Athanassiou, A. E. Bafaloukos, D. Pectasides, D. Dimitriadis, M. Varthalitis, I. Barbounis, V. First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. |
title | First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. |
title_full | First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. |
title_fullStr | First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. |
title_full_unstemmed | First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. |
title_short | First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. |
title_sort | first line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247295/ https://www.ncbi.nlm.nih.gov/pubmed/2803952 |
work_keys_str_mv | AT athanassiouae firstlinecombinationchemotherapywithcisplatinandetoposideinadvancedovariancancer AT bafaloukosd firstlinecombinationchemotherapywithcisplatinandetoposideinadvancedovariancancer AT pectasidesd firstlinecombinationchemotherapywithcisplatinandetoposideinadvancedovariancancer AT dimitriadism firstlinecombinationchemotherapywithcisplatinandetoposideinadvancedovariancancer AT varthalitisi firstlinecombinationchemotherapywithcisplatinandetoposideinadvancedovariancancer AT barbounisv firstlinecombinationchemotherapywithcisplatinandetoposideinadvancedovariancancer |